BNP Paribas Financial Markets
INDV icon

BNP Paribas Financial Markets’s Indivior Pharmaceuticals INDV Stock Holding History

BNP Paribas Financial Markets’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.57M Sell
135,650
-693,241
-84% -$25.1M ﹤0.01% 2019
2026
Q1 		$25.3M Buy
+828,891
New +$27.4M 0.01% 1012

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Financial Markets's INDV Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Indivior Pharmaceuticals (INDV) stake by 84% in Q2 2026, selling an estimated $25.1M and leaving 135,650 shares worth $5.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2019.

BNP Paribas Financial Markets first reported a position in INDV in Q1 2026 and has held it in 2 quarters since. The position peaked at $25.3M in Q1 2026. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • BNP Paribas Financial Markets held 135,650 shares of Indivior Pharmaceuticals worth $5.57M as of Q2 2026.
  • BNP Paribas Financial Markets sold 693,241 Indivior Pharmaceuticals shares in Q2 2026, an estimated $25.1M.
  • Indivior Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #2019 holding.
  • BNP Paribas Financial Markets first reported a position in Indivior Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • BNP Paribas Financial Markets's Indivior Pharmaceuticals position peaked at $25.3M in Q1 2026.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.